Sanofi and Bristol-Myers Squibb have restructured their alliance following the patent expiry of Plavix and Avapro/Avalide in many major markets. Effective January 1, 2013, BMS will return rights to Sanofi in all markets except Plavix in the U.S. and PR, giving Sanofi the freedom to operate commercially. BMS will receive royalties on Sanofi’s sales of branded and unbranded Plavix, Avapro/Avalide worldwide through 2018, and will receive a terminal payment of $200 million in December 2018.   “Brist...